Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter L Thompson

Showing results (11-20 of 140) with videos related to

Pageof 14
Sort By:
The Medical Journal of Australia|May 7, 2013
J-curve revisited: cardiovascular benefits of moderate alcohol use cannot be dismissedPeter L Thompson
Clinical Therapeutics|September 20, 2014
Atrial fibrillation: risk is still not well controlled let alone ablatedPeter L Thompson, Rukshen Weerasooriya
The Medical Journal of Australia|November 13, 2014
Eight challenges faced by general practitioners caring for patients after an acute coronary syndromeAlistair Vickery, Peter L Thompson
The Medical Journal of Australia|January 12, 2017
Encouraging early treatment of suspected heart attack: it's OK to call 000Peter L Thompson, Trevor Shilton
Current Opinion in Lipidology|November 21, 2002
Early initiation of statin therapy after a coronary eventBarry McKeown, Peter L Thompson
The American Journal of Cardiology|March 14, 2007
Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery diseaseMark Nidorf, Peter L Thompson
Clinical Therapeutics|November 6, 2023
Atherosclerosis: More Challenging and Complex Than We ThoughtPeter L Thompson, Juliana Hamzah
Current Opinion in Lipidology|October 16, 2018
Colchicine: an affordable anti-inflammatory agent for atherosclerosisPeter L Thompson, S Mark Nidorf
Panminerva Medica|December 15, 2015
Antithrombotic therapy in patients with combined coronary heart disease and atrial fibrillationPeter L Thompson, Allison C Morton
Journal of Thoracic Disease|April 3, 2018
Anti-inflammatory therapy with canakinumab for atherosclerotic disease: lessons from the CANTOS trialPeter L Thompson, S Mark Nidorf
Pageof 14

Showing results (11-20 of 140) with videos related to

Sort By:
Pageof 14
The Medical Journal of Australia|May 7, 2013
J-curve revisited: cardiovascular benefits of moderate alcohol use cannot be dismissedPeter L Thompson
Clinical Therapeutics|September 20, 2014
Atrial fibrillation: risk is still not well controlled let alone ablatedPeter L Thompson, Rukshen Weerasooriya
The Medical Journal of Australia|November 13, 2014
Eight challenges faced by general practitioners caring for patients after an acute coronary syndromeAlistair Vickery, Peter L Thompson
The Medical Journal of Australia|January 12, 2017
Encouraging early treatment of suspected heart attack: it's OK to call 000Peter L Thompson, Trevor Shilton
Current Opinion in Lipidology|November 21, 2002
Early initiation of statin therapy after a coronary eventBarry McKeown, Peter L Thompson
The American Journal of Cardiology|March 14, 2007
Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery diseaseMark Nidorf, Peter L Thompson
Clinical Therapeutics|November 6, 2023
Atherosclerosis: More Challenging and Complex Than We ThoughtPeter L Thompson, Juliana Hamzah
Current Opinion in Lipidology|October 16, 2018
Colchicine: an affordable anti-inflammatory agent for atherosclerosisPeter L Thompson, S Mark Nidorf
Panminerva Medica|December 15, 2015
Antithrombotic therapy in patients with combined coronary heart disease and atrial fibrillationPeter L Thompson, Allison C Morton
Journal of Thoracic Disease|April 3, 2018
Anti-inflammatory therapy with canakinumab for atherosclerotic disease: lessons from the CANTOS trialPeter L Thompson, S Mark Nidorf
Pageof 14